Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 Guidance

    Question

    Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 Guidance

    Direct answer

    Dentsply Sirona delivered an earnings beat for Q2, generating adjusted EPS of $0.52 compared to analyst consensus of $0.36. Top-line revenue declined 4.1% year-over-year, reflecting broader volume headwinds in select dental equipment lines. Wellspect Healthcare provided an operational offset with 7.1% growth. Management maintained full-year 2026 guidance, reaffirming sales expectations of $3.5 billion to $3.6 billion and adjusted earnings per share between $1.40 and $1.50.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 Guidance”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-tops-q2-eps-at-0-52-vs-0-36-consensus-and-affirms-fy2026-guidanc-ece24c

    EQUITY
    Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 Guidance
    Dentsply Sirona delivered an earnings beat for Q2, generating adjusted EPS of $0.52 compared to analyst consensus of $0.36. Top-line revenue declined 4.1% year-over-year, reflecting broader volume headwinds in select dental equipment lines. Wellspect Healthcare provided an operational offset with 7.1% growth. Management maintained full-year 2026 guidance, reaffirming sales expectations of $3.5 billion to $3.6 billion and adjusted earnings per share between $1.40 and $1.50.
    XRAYALGN
    Impact
    70
    SEP 9
    SIG
    88%
    XRAYALGN
    Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 Guidance
    Dentsply Sirona delivered an earnings beat for Q2, generating adjusted EPS of $0.52 compared to analyst consensus of $0.36. Top-line revenue declined 4.1% year-over-year, reflecting broader volume headwinds in select dental equipment lines. Wellspect Healthcare provided an operational offset with 7.1% growth. Management maintained full-year 2026 guidance, reaffirming sales expectations of $3.5 billion to $3.6 billion and adjusted earnings per share between $1.40 and $1.50.
    → Adjusted Q2 EPS outperformance of 16 cents against consensus offsets top-line contraction of 4.1%, stabilizing XRAY valuation around affirmed $1.40-$1.50 full-year guidance.
    Impact
    Dentsply Sirona delivered an earnings beat for Q2, generating adjusted EPS of $0.52 compared to analyst consensus of $0.36. Top-line revenue declined 4.1% year-over-year, reflecting broader volume headwinds in select dental equipment lines. Wellspect Healthcare provided an operational offset with 7.1% growth. Management maintained full-year 2026 guidance, reaffirming sales expectations of $3.5 billion to $3.6 billion and adjusted earnings per share between $1.40 and $1.50.
    Affected
    XRAYALGN
    Transmission
    Adjusted Q2 EPS outperformance of 16 cents against consensus offsets top-line contraction of 4.1%, stabilizing XRAY valuation around affirmed $1.40-$1.50 full-year guidance.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYoperating margin resilience offsetting top-line revenue declineUp1-5dQ2 adjusted EPS of $0.52 beat consensus of $0.36 with affirmed full-year EPS guidance of $1.40-$1.50.
    ALGNdental equipment end-demand read-acrossWatch1-5dXRAY dental revenue contraction of 4.1% reflects ongoing dental demand conditions.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYUpdisagreed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month